Daiwa Securities Group Inc. Has $1.04 Million Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Daiwa Securities Group Inc. lessened its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 11.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,267 shares of the biotechnology company’s stock after selling 410 shares during the quarter. Daiwa Securities Group Inc.’s holdings in United Therapeutics were worth $1,041,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the company. Norges Bank bought a new stake in United Therapeutics in the fourth quarter valued at about $100,519,000. LSV Asset Management increased its holdings in United Therapeutics by 82.5% in the second quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock valued at $307,837,000 after purchasing an additional 436,851 shares during the last quarter. Swedbank AB bought a new stake in United Therapeutics in the first quarter valued at about $97,316,000. Nordea Investment Management AB increased its holdings in United Therapeutics by 677.6% in the first quarter. Nordea Investment Management AB now owns 300,920 shares of the biotechnology company’s stock valued at $72,422,000 after purchasing an additional 262,222 shares during the last quarter. Finally, Avidity Partners Management LP bought a new stake in United Therapeutics in the fourth quarter valued at about $52,158,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Buying and Selling

In related news, Director Nilda Mesa sold 266 shares of the stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $318.58, for a total transaction of $84,742.28. Following the completion of the transaction, the director now directly owns 5,107 shares of the company’s stock, valued at $1,626,988.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Nilda Mesa sold 266 shares of the stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $318.58, for a total transaction of $84,742.28. Following the completion of the transaction, the director now directly owns 5,107 shares of the company’s stock, valued at $1,626,988.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Raymond Dwek sold 5,000 shares of the stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $325.35, for a total value of $1,626,750.00. Following the transaction, the director now directly owns 1,750 shares of the company’s stock, valued at $569,362.50. The disclosure for this sale can be found here. Over the last three months, insiders sold 114,522 shares of company stock worth $37,671,474. 12.50% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Wells Fargo & Company upped their price objective on United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a report on Tuesday, August 20th. StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, August 2nd. TD Cowen increased their price target on United Therapeutics from $270.00 to $350.00 and gave the stock a “buy” rating in a report on Thursday, July 11th. Bank of America lowered their price target on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a report on Thursday, August 1st. Finally, LADENBURG THALM/SH SH downgraded United Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 1st. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $350.36.

United Therapeutics Stock Down 0.6 %

NASDAQ:UTHR opened at $339.12 on Monday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.18 and a current ratio of 4.35. The company has a market cap of $15.09 billion, a PE ratio of 16.03, a PEG ratio of 1.23 and a beta of 0.57. United Therapeutics Co. has a 52-week low of $208.62 and a 52-week high of $366.08. The stock has a 50-day simple moving average of $336.73 and a 200 day simple moving average of $287.95.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). The firm had revenue of $714.90 million for the quarter, compared to the consensus estimate of $691.87 million. United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The firm’s quarterly revenue was up 19.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $5.24 earnings per share. On average, sell-side analysts expect that United Therapeutics Co. will post 24.86 EPS for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.